Inhibition of Immunoproteasome Attenuates NLRP3 Inflammasome Response by Regulating E3 Ubiquitin Ligase TRIM31
Cells · 2024
DOI: 10.3390/cells13080675 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2024. Verfasst von Yubin Lee und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioscience and Biotechnology, Konkuk University, 120 Neungdong-ro, Gwangjin-gu, Seoul 05029, Republic of Korea. Hauptthemen laut MEDLINE: NLR Family, Pyrin Domain-Containing 3 Protein, Ubiquitin-Protein Ligases, Tripartite Motif Proteins, Inflammasomes. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, NIH HHS, National Research Foundation of Korea.
Abstract (Originalsprache)
Excessive secretion of pro-inflammatory cytokines leads to the disruption of intestinal barrier in inflammatory bowel disease (IBD). The inflammatory cytokine tumor necrosis factor alpha (TNFα) induces the assembly of the NLRP3 inflammasome, resulting in the augmented secretion of inflammatory cytokines implicated in the pathogenesis of inflammatory bowel disease (IBD). TNFα has also been known to induce the formation of immunoproteasome (IP), which incorporates immunosubunits LMP2, LMP7, and MECL-1. Inhibition of IP activity using the IP subunit LMP2-specific inhibitor YU102, a peptide epoxyketone, decreased the protein levels of NLRP3 and increased the K48-linked polyubiquitination levels of NLRP3 in TNFα-stimulated intestinal epithelial cells. We observed that inhibition of IP activity caused an increase in the protein level of the ubiquitin E3 ligase, tripartite motif-containing protein 31 (TRIM31). TRIM31 facilitated K48-linked polyubiquitination and proteasomal degradation of NLRP3 with an enhanced interaction between NLRP3 and TRIM31 in intestinal epithelial cells. In addition, IP inhibition using YU102 ameliorated the symptoms of colitis in the model mice inflicted with dextran sodium sulfate (DSS). Administration of YU102 in the DSS-treated colitis model mice caused suppression of the NLRP3 protein levels and accompanied inflammatory cytokine release in the intestinal epithelium. Taken together, we demonstrated that inhibiting IP under inflammatory conditions induces E3 ligase TRIM31-mediated NLRP3 degradation, leading to attenuation of the NLRP3 inflammatory response that triggers disruption of intestinal barrier.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Bioscience and Biotechnology, Konkuk University, 120 Neungdong-ro, Gwangjin-gu, Seoul 05029, Republic of Korea.
- Department of Cellular & Molecular Medicine, Herbert Wertheim College of Medicine, Center for Translational Science at Port St. Lucie, Florida International University, 11350 SW Village Pkwy, Port St. Lucie, FL 34987, U…
ORCID-Profile: Yubin Lee, Sumin Son, Dong-Eun Kim
Förderung
- NIA NIH HHS
- NIH HHS
- National Research Foundation of Korea
- Korean government
- NIH/NIA
Zitieren
APA
Lee, Y., Yoon, B., Son, S., Cho, E., Kim, K. B., Choi, E. Y., & Kim, D. E. (2024). Inhibition of Immunoproteasome Attenuates NLRP3 Inflammasome Response by Regulating E3 Ubiquitin Ligase TRIM31. Cells. https://doi.org/10.3390/cells13080675
Vancouver
Lee Y, Yoon B, Son S, Cho E, Kim KB, Choi EY, et al. Inhibition of Immunoproteasome Attenuates NLRP3 Inflammasome Response by Regulating E3 Ubiquitin Ligase TRIM31. Cells. 2024. doi:10.3390/cells13080675
BibTeX
@article{Lee2024,
author = {Lee, Yubin and Yoon, Boran and Son, Sumin and Cho, Eunbin and Kim, Kyung Bo and Choi, Eun Young and Kim, Dong-Eun},
title = {Inhibition of Immunoproteasome Attenuates NLRP3 Inflammasome Response by Regulating E3 Ubiquitin Ligase TRIM31},
journal = {Cells},
year = {2024},
doi = {10.3390/cells13080675}
}
EUVIMED